Interestingly, the dormancy regulator (Nr2f1) first identified in a murine prostate cancer model also serves as a biomarker for dormant DTCs in breast cancer patients [17, 30], suggesting that while there are clear differences between the cancer types, there may be common dormancy-related genes. This evidence concerns the gene NR2F1 and Familial prostate cancer.